V12 SENTINEL ENGINE · AI MARKET ANALYSIS
Row
H
HIMSAI Stock Diagnostic Report

Hims & Hers Health resumed at JP Morgan at neutral on GLP-1 compounding headwinds

JPMorgan resumed coverage on Hims & Hers Health with a neutral opinion due to headwinds related to GLP-1 copycat drugs.

View Source Article ↗
AI CATALYST SCORE50 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+
ANALYSIS HISTORY

HIMS Analysis History (Last 30 Days)

Diagnosed AtTickerAI ScoreTier
2026-10-09 21:09:20HIMS55MidView Report →
2026-10-07 21:07:03HIMS35RowView Report →
2026-09-11 13:28:57HIMS50RowView Report →
View Full History for HIMS (Blueprint) →